Citigroup's decision to maintain a Buy rating on Lexicon Pharmaceuticals and raise the price target from $6 to $8 indicates a positive outlook for the company's stock. This news is likely to have a positive impact on LXRX's stock price in the short term as it reflects increased confidence in the company's prospects by a major financial institution.